Blood Analyzers

Germaine Laboratories, Inc. is an FDA-registered manufacturer and distributor of in vitro diagnostic tests and reagents serving medical, drug testing, veterinary, and food & beverage industries since 1990. The company holds ISO 13485:2016 certification for quality management systems applicable to diagnostic test manufacturing. Product portfolio includes urinalysis reagent strips (AimStrip®), hemoglobin testing systems (AimStrip® Hemoglobin), strep detection tests (StrepAim®), pregnancy tests (AimStep®), blood glucose monitoring systems (VQPet H for veterinary use), COVID-19 antigen home tests (Flowflex™), and reducing substance tablets for food testing (AimTab™). The company serves physician offices, walk-in clinics, pharmacies, hospitals, drug court programs, schools, workplaces, veterinary practices, and food & beverage manufacturers. All products are CLIA-waived where applicable and FDA-approved. Germaine Laboratories operates as both a manufacturer and distributor, offering bulk packaging, private labeling, OEM arrangements, and exclusive distributorship opportunities. The company provides laboratory services and tableting contract manufacturing capabilities. Customer service and technical support are available 24/7 via phone and email, with emphasis on rapid response and order fulfillment.

Guardant Health is a precision oncology company specializing in blood-based liquid biopsy testing for cancer detection, staging, and treatment monitoring. The company develops and commercializes circulating tumor DNA (ctDNA) tests that enable early cancer screening and inform treatment decisions across all stages of disease. Their primary product lines include Shield (cancer screening via blood test), Guardant Complete (advanced cancer oncology testing), and BioPharma Solutions for drug development and clinical trials. With over 500,000 tests performed and 12,000 physicians utilizing their platform, Guardant Health provides data-driven insights to improve clinical outcomes through biomarker analysis and minimal residual disease (MRD) detection. The company operates a CLIA-certified laboratory in the Bay Area and maintains regulatory compliance for commercialized diagnostics. Their technology supports personalized cancer care by identifying genetic mutations, tumor characteristics, and treatment response markers from blood samples, reducing reliance on invasive tissue biopsies and enabling earlier intervention.

Newmarket Biomedical Ltd is a British in-vitro diagnostic (IVD) reagents and test kits manufacturer established in 2011. The company specializes in the worldwide manufacture, sale, and distribution of diagnostic kits and laboratory products, with particular expertise in syphilis serology testing. Core product lines include RPR (rapid non-treponemal particle agglutination) tests, TPHA (passive particle agglutination assays for Treponema pallidum detection), Syphilis EIA Total Antibody tests, and bulk reagents available upon request. Newmarket Biomedical holds ISO 13485 and MDSAP certifications, with QMS recertification valid until 2027. The company is IVDR-compliant for TPHA and RPR kits, demonstrating adherence to EU in-vitro diagnostic regulations. Products are distributed globally across the UK, USA, Canada, EU, India, Australia, Vietnam, Philippines, South Africa, and other territories. The company maintains quality assurance and regulatory compliance standards suitable for clinical laboratory, research, and diagnostic applications.

LifeSouth Community Blood Centers is a regional blood bank and transfusion services provider serving hospital and healthcare systems across Florida and the Southeast. The organization collects, tests, processes, and distributes whole blood and blood components (including platelets and double red cells) to hospital partners. Core services include patient blood management, laboratory services, autologous and directed transfusion, therapeutic apheresis, and cord blood banking. LifeSouth operates a network of donor centers and mobile blood collection units (BloodMobiles) and manages a comprehensive donor recruitment program. The organization provides hospital partners with online ordering portals, product codes, and clinical support for transfusion-related activities. Additionally, LifeSouth operates a research institute focused on blood-related and autoimmune disease research, offers a Specialist in Blood Banking Certificate Program, and maintains a community foundation. The organization is accredited and licensed to manufacture and distribute blood products under FDA and AABB regulations. LifeSouth markets wellness screening (A1c diabetes testing) alongside donation to expand community health engagement.

CareDx is a transplant-focused diagnostic and digital health company providing comprehensive solutions across the entire transplant journey. The company delivers advanced diagnostics including rejection monitoring tests and HLA typing kits, digital health platforms, and transplant pharmacy services. CareDx reports performing over 1 million rejection monitoring tests annually, selling approximately 200,000 HLA typing kits per year, and filling 150,000 prescriptions through its transplant pharmacy division. The platform serves approximately 70% of transplant centers with one or more software products. Products and solutions span diagnostic testing, digital workflow platforms, lab innovations, and clinical decision support tools. The company combines laboratory testing capabilities with software platforms designed to simplify clinical workflows and personalize patient care throughout transplant management. CareDx operates as an integrated provider offering both diagnostic services and digital health infrastructure for transplant programs, including pre-transplant evaluation, post-transplant monitoring, and rejection surveillance.

Diagnostic Automation / Cortez Diagnostics, Inc. (DACD) is a global diagnostic test kit manufacturer founded in 1989, serving research labs, hospitals, clinical laboratories, and physicians across 168 countries. The company specializes in producing ELISA kits, rapid test kits, chemiluminescence immunoassay (CLIA) kits, serology tests, and immunofluorescence assay (IFA) kits. DACD offers both consumable diagnostic test kits and associated instruments for clinical laboratory use. The product portfolio addresses infectious disease serology, immunological testing, and general clinical diagnostics. The company emphasizes quality assurance, competitive pricing, fast shipping, and technical customer support. DACD maintains manufacturing and distribution operations from its Woodland Hills, California headquarters and distributes globally through a network of respected distributors. The company is privately held and committed to continuous innovation in diagnostic testing methodologies.

ELITechGroup is a global in-vitro diagnostics (IVD) manufacturer serving hospitals and diagnostic laboratories in over 100 countries. Owned by Bruker Corporation, the company develops, manufactures, and distributes diagnostic instruments, reagents, and software across three specialized business divisions: Molecular Diagnostics (MDx), Biomedical Systems (EBS), and Microbiology (EM). With approximately 600 global professionals, ELITechGroup addresses laboratory diagnostic needs including molecular testing, clinical chemistry, immunoassay, and microbiology analysis. The company operates as part of Bruker Microbiology & Infection Diagnostics division (BMID), combining advanced diagnostic technologies with sample-to-result automation and high-throughput instrumentation. Products serve clinical laboratories, hospital diagnostics departments, and reference laboratories requiring FDA-cleared and CE-marked diagnostic solutions. The company maintains regional sales offices across North America, Europe, Australia/New Zealand, and Asia-Pacific.

Randox Laboratories is a global leader in diagnostic solutions with over 40 years of expertise in clinical laboratory, molecular, and point-of-care diagnostics. The company manufactures a comprehensive portfolio including the RX Series clinical chemistry analyzers, Vivalytic molecular point-of-care systems, and Evidence Series immunoassay analyzers. Randox provides open-channel reagents covering more than 100 disease areas including autoimmune disorders, cancers, and emergency/critical care diagnostics. The company operates as the world's largest external quality assessment (EQA) provider through RIQAS and QCMD platforms, serving over 100,000 users across 145 countries. Core offerings include quality control solutions (Acusera brand), third-party diagnostic assays, molecular infectious disease controls, and QC data management software. Beyond laboratory equipment, Randox operates multiple specialized service divisions: Contract Manufacturing (OEM partnerships), CDx and Biopharma services (biomarker development), Genomics (end-to-end sequencing with in-house bioinformatics), Pathology Services (sample collection and advanced testing), Toxicology (forensic drug detection for 600+ substances), Workplace Drug and Alcohol Testing, Food Diagnostics (antimicrobial and toxin screening), and Randox Health (preventative healthcare and home testing kits). The company serves clinical laboratories, reference labs, pharmaceutical companies, food/beverage industry, workplace testing, and forensic applications globally.

Acro Biotech, Inc. is a medical diagnostics manufacturer based in Montclair, California, specializing in point-of-care and clinical laboratory testing solutions. The company develops and distributes a diverse portfolio of diagnostic analyzers and rapid testing systems across multiple therapeutic and clinical domains. Product lines include respiratory infection rapid tests (COVID-19 and other respiratory panels, though COVID tests are not FDA-cleared for US distribution), drugs of abuse screening tests, cardiac biomarker assays, urine analyzers, fluorescence immunoassay analyzers, and multiparameter handheld meters for hemoglobin, cholesterol, uric acid, and glucose testing. The company also offers solutions for women's health, infectious disease serology, tumor markers, and veterinary diagnostics. Key analyzer platforms include the ATR-ACO300 urine analyzer, AFR-600 fluorescence immunoassay system (Apoti), AHR-100 multiparameter meter for hemoglobin/cholesterol/uric acid/glucose, and LF Reader systems. The company serves clinical laboratories, point-of-care testing facilities, and veterinary markets with rapid testing and automated laboratory equipment. No specific FDA 510(k) clearances, ISO certifications, or CE Mark designations are stated on the website. Manufacturing capabilities and regulatory status for products marketed outside the US are not detailed in available content.

Since 1986, Jant Pharmacal Corporation has been a leading B2B supplier of point-of-care (POC) diagnostic tests and laboratory instrumentation to U.S. and international healthcare settings. The company operates two primary divisions: POC Division and Lab Division. The POC Division offers CLIA-waived rapid tests and analyzers for use in physicians' offices, clinics, urgent care centers, and hospitals under registered trademarks Accutest, Accustrip, and LipidPlus. Product categories include cardiac testing, colorectal cancer screening, drugs of abuse, hypothyroidism, infectious diseases, pregnancy & fertility, and urinalysis. The Lab Division provides integrated solutions for laboratory optimization, featuring clinical chemistry, hematology, immunoassay, toxicology, urinalysis, and molecular diagnostic systems with reagents and consumables. The company holds GPO supplier contracts with Vizient and Champs, representing over 500,000 members. Additionally, Jant offers laboratory consultation services including financial feasibility assessment, turn-key laboratory setup, CLIA compliance consultation, LCMS method development, and laboratory information system integration.

Isla Lab Products, LLC is a Puerto Rico–based medical laboratory distributor and supplier founded in 1977 and expanded to the Caribbean in 2007. Headquartered at Amelia Industrial Park in Guaynabo, PR, the company operates a 30,000-square-foot facility with sales, customer service, technical and professional support, cold chain distribution, conference facilities, and a training center. The company distributes and supplies a comprehensive portfolio of clinical laboratory analyzers, reagents, consumables, and diagnostics across multiple specialties: clinical chemistry, immunochemistry, microbiology, hematology, transfusion medicine and blood banking, point-of-care testing, molecular diagnostics, pathology, toxicology, coagulation studies, COVID-19 testing, and rapid diagnostics. Key product offerings include automated chemistry analyzers (cobas® c 513, cobas® pure), microbiology identification and blood culture systems (VITEK® 2, BACT/ALERT® VIRTUO®, BACT/ALERT® 3D), rapid antigen testing platforms (Quidel Sofia 2), blood collection tubes (Vacuette®), and hematology analyzers (BC-5390). The company serves clinical laboratories, hospitals, diagnostic centers, and healthcare institutions across Puerto Rico and the Caribbean islands. Isla Lab Products maintains technical service capabilities, professional training, and cold chain logistics to support customer operations. The company operates as an authorized distributor for major in vitro diagnostics manufacturers and provides B2B procurement solutions for laboratory testing infrastructure and consumables.

Gentech Biomedical is a Puerto Rico-based clinical laboratory equipment distributor and service provider with over 32 years of operational history. The company supplies hematology analyzers (Sysmex XS1000i, Cell Dyn Ruby refurbished units), microscopes (ACCU-SCOPE EXC Series, 3012-LED), centrifuges (LW Scientific E8, MX5), blood mixers, digital cell counters, bench-top incubators, temperature/data logging systems (LogTag recorders), NIST-calibrated thermometers, and reagents for major equipment brands including Sysmex and Cell Dyn. The company also provides autoclavable mechanical pipettes in various volumes and custom reagent solutions. Beyond equipment sales, Gentech offers comprehensive technical support services including equipment maintenance, preventative maintenance programs, flexible service contracts, and replacement unit deployment for facilities across Puerto Rico and the Caribbean. Support covers major diagnostic brands: Sysmex, Cell-Dyn, Siemens Clinitek, Medika, Thermo, Helmer, and Baxter/Dade. Operations are certified under ISO 9001:2015 quality management standards, ensuring consistent reliability and compliance. The company targets hospitals, clinical laboratories, and diagnostic institutions requiring cost-effective solutions without quality compromise.

Beckman Coulter Diagnostics is a global leader in clinical diagnostics and biomedical testing, headquartered in Brea, California. A subsidiary of Danaher Corporation since its foundational 1935 establishment, the company develops, manufactures, and distributes innovative laboratory automation systems, analyzers, and informatics solutions for clinical and research laboratories worldwide. The company specializes in clinical chemistry systems, immunoassay instruments, hematology analyzers, urinalysis systems, microbiology solutions, blood banking instruments, and protein chemistry platforms. Beckman Coulter also provides total lab automation systems (DxA 5000 series), advanced informatics middleware (Remisol Advance), and remote diagnostic services. Its comprehensive portfolio supports healthcare professionals and laboratory teams in disease diagnosis, treatment decisions, patient monitoring, and improved health outcomes. With annual revenue of approximately $2.9 billion, the company emphasizes efficiency, automation, clinical confidence, and integrated workflow solutions for hospital laboratories, reference laboratories, and blood banks globally.

Biobase Biodustry (Shandong) Co., Ltd is a high-tech manufacturer founded in 1999, headquartered in Jinan, Shandong, China. The company operates 25 manufacturing facilities and provides comprehensive one-stop solutions for laboratory, medical, and clinical applications. Core product categories include biological safety cabinets, laminar flow cabinets, fume hoods, sterilization equipment (autoclaves, sterilizers), clinical and analytical instruments (auto chemistry analyzers, electrolyte analyzers, blood bank refrigerators), flow cytometers, PCR cabinets, laboratory cryogenic refrigeration units, and hospital furniture (beds, wheelchairs). Biobase serves research institutions, clinical laboratories, diagnostic facilities, and healthcare providers across more than 190 countries. The company maintains in-house R&D (100+ employees), sales (200+ employees), and after-sales support teams (11+ employees). Certifications include ISO 9001, ISO 13485, ISO 14001, CE, FDA, NSF, SGS, and EN standards, reflecting compliance with international quality and medical device regulations. Services include 24-hour online customer support and warranty coverage for defective components.

Awareness Technology, Inc. is an ISO 13485:2016 certified manufacturer of in vitro diagnostic (IVD) instruments, reagents, and assays established in 1982. Based in Palm City, Florida, the company specializes in automated and semi-automated clinical laboratory systems tailored for small- to medium-sized labs. Core product lines include chemistry analyzers, microplate readers, microplate washers, and incubator/shakers. The company manufactures ELISA reagents, biochemistry kits, and specialized chemiluminescence and automated RPR analyzers. Awareness Technology provides full-service OEM production capabilities with custom instrument design, field-proven reliability, ease of use, and cost-effective solutions. The company serves over 200 countries across Asia, Africa, the Middle East, and the South Pacific, supporting routine health screening, autoimmune testing, infectious disease detection, and food science testing applications.

MedicalSystem Biotechnology Co., Ltd. is a global in-vitro diagnostics (IVD) solution provider founded in Ningbo, China, in 2003. The company operates a complete value chain from R&D through commercial services, serving clinical laboratories, hospitals, and diagnostic centers across 100+ countries. With ~2,500 employees globally and 22+ years of IVD experience, MedicalSystem specializes in automated clinical laboratory analyzers for biochemistry, chemiluminescence immunoassay, and blood lipid subfraction analysis. Primary product lines include the MS-380P (compact fully-automated chemistry analyzer), MS-i2280 (chemiluminescence immunoassay system integrating reagents and instruments), and VAP Series (advanced analyzers for cardiovascular risk assessment via lipid subfractionation). The company emphasizes reliable, easy-to-use diagnostic solutions designed for continuous laboratory operations. Products combine instrumentation with reagents to support accurate clinical decision-making across diverse laboratory settings. Manufacturing and service capabilities span R&D, production, quality assurance, and after-sales support. No specific FDA 510(k), CE, or ISO certifications are stated on the fetched content, though the company's international distribution and regulatory compliance are implied by presence in 100+ countries.

DiaSorin Inc. is a global leader in laboratory diagnostics, specializing in immunodiagnostics and molecular diagnostics platforms. The company develops and manufactures diagnostic assays and analyzers for infectious diseases, immunological disorders, and other clinical applications. Core product lines include the LIAISON® automated immunoassay analyzer platform, Simplexa® molecular diagnostic kits for detection of viral pathogens (COVID-19, Flu A/B, RSV, HSV, CMV), and QuantiFERON® TB Gold Plus for tuberculosis detection. DiaSorin also offers the LIAISON® MeMed BV® for rapid bacterial-viral differentiation and LIAISON® BRAHMS PCT® for infection triage. The company operates the Luminex division, providing xMAP® multiplex assay technology platforms (xMAP INTELLIFLEX®) for biomedical research, clinical diagnostics, and drug discovery applications, including custom assay design and development services. Products address hospital laboratories, clinical diagnostic centers, and research institutions. The company maintains CLIA-waived status for certain molecular tests and holds FDA clearances and international regulatory approvals (CE marking). Manufacturing and distribution capabilities support North American and global markets.

Precision Diabetes, Inc. is an emerging leader in precision medicine for diabetes, headquartered in Raleigh, North Carolina (Research Triangle Park). The company develops and markets novel diabetes biomarkers and diagnostic tests that span diabetes risk assessment through complication detection. Primary product is GlycoMark, a proprietary diabetes biomarker test for which Precision Diabetes holds exclusive distribution rights across the United States, Europe, Australia, Asia-Pacific, Middle East, and Mexico. GlycoMark is validated as a prediabetes biomarker and novel indicator of SGLT-2 inhibitor adherence; recent clinical data suggests utility in COVID-19 severity assessment. The company also partners with Patia Europe to distribute DIABETESpredict (type 2 diabetes genetic testing) and Matergen (gestational diabetes genetic testing) in the U.S. market. Precision Diabetes maintains a strategic partnership with DxGen Corp. to commercialize a point-of-care diabetes testing analyzer. The portfolio addresses both clinical laboratory and point-of-care testing modalities, serving endocrinology, primary care, and hospital laboratory markets. Company demonstrates active clinical research engagement, with publications and presentations at major conferences including the American Diabetes Association.

HORIBA is a multinational group providing analytical and diagnostic instruments, systems, and solutions across multiple sectors. In healthcare, HORIBA specializes in in vitro diagnostic systems including hematology analyzers (Yumizen H-series), which support clinical laboratory diagnostics for various user types: patients, physicians, private laboratories, clinics, and university hospitals. The company manufactures blood analyzers, hematology systems, and related laboratory instrumentation with demonstrated clinical utility in disease detection and monitoring. Beyond healthcare, HORIBA operates across automotive R&D (mobility), environmental and process monitoring, semiconductor manufacturing metrology, scientific instruments, and life science applications. The organization offers optical spectroscopy solutions (including custom-configured spectrometers, monochromators, and CCD systems), OEM spectroscopy and imaging components (gratings, spectrometers, cameras from VUV to NIR), and particle size analyzers. HORIBA maintains a global footprint with multiple subsidiaries and operations worldwide. The company demonstrates commitment to quality and regulatory compliance in clinical diagnostics, evidenced by product development workshops and clinical case studies supporting transfusion safety and diagnostic accuracy.

Catachem Inc. is a U.S.-based manufacturer of clinical chemistry reagents and diagnostic products for automated analyzers serving both veterinary and human research use only (RUO) markets. With over 40 years of diagnostic manufacturing experience, the company specializes in formulating reagents, calibrators, and controls tailored to customer-specific needs. Product lines include clinical chemistry reagents for veterinary diagnostics, RUO human diagnostics, calibrators and controls for automated and semi-automated analyzers, and ethylene glycol assay kits in multiple configurations. The company also provides contract lyophilization services (CDMO) for custom product development. Catachem's reagents are designed for accuracy, precision, stability, and cost-effectiveness across multiple analyzer platforms. The company emphasizes responsive customer service and technical support. Primary markets include veterinary diagnostic laboratories, research institutions, and clinical laboratory suppliers. All human diagnostic products are clearly designated for research use only, not for current diagnostic procedures.

Monobind Inc. is a leading independent in vitro diagnostics (IVD) manufacturer founded in 1978 and headquartered in Lake Forest, California. The company develops and manufactures over 160 immunoassay products across its AccuBind® ELISA and AccuLite® CLIA platforms, serving clinical laboratories, point-of-care facilities, and direct-to-patient applications globally. Monobind's portfolio spans multiple assay formats—microplate, monotest, magnetic-bead, lateral flow assays (LFA), and microarray technologies—enabling testing of serum, plasma, and whole blood samples. The company supports scalable workflows from manual reader-based systems to fully automated random-access analyzers. Beyond finished assays, Monobind supplies high-quality biomaterials and specialty reagents including buffers and stabilizers for the global diagnostics industry. Operating under FDA registration and ISO 13485 certification, the company distributes CE-marked products to laboratories and partners in over 100 countries worldwide.

Saladax Biomedical, Inc. is a biotechnology company specializing in therapeutic drug monitoring (TDM) assays for psychiatry and oncology. The company develops and manufactures rapid blood-level measurement tests that optimize drug dosing for essential medications prescribed by psychiatrists and oncologists. Key products include the My5-FU Assay for monitoring 5-Fluorouracil chemotherapy (Health Canada approved, May 2024) and MyCare™ Insite for clozapine monitoring with point-of-care testing capabilities, delivering results in hours rather than days. Saladax supports personalized medicine initiatives through companion diagnostics and clinical trial collaborations with pharmaceutical partners. The company's TDM solutions enable clinicians to confirm medication adherence, optimize dosing regimens, and reduce toxicity risks, improving patient outcomes in psychiatric and oncological care. International distribution partnerships expand access across multiple regions.

R&D Systems is a leading provider of high-quality reagents and tools for life science research, established in 1976 in Minneapolis, Minnesota. As a key brand under Bio-Techne, the company specializes in products for basic, translational, and clinical research across cancer, immunology, and neuroscience. R&D Systems offers a comprehensive catalog including recombinant proteins, validated antibodies, ELISA kits, and specialized reagents for stem cell research and cell signaling. The company pioneered commercial release of the first recombinant cytokine, TGF-beta 1, in 1985. Operating a GMP-grade manufacturing facility in Saint Paul, MN, with global subsidiaries in the UK, Germany, France, and China, R&D Systems supports researchers in academic, biotech, and pharmaceutical sectors with over 500,000 products. The company provides application-specific validated antibodies, immunoassay kits, custom reagent development, and advanced analytical instruments for quantitative protein analysis and biomarker detection.

Ansh Labs, a VION Biosciences company based in Webster, Texas, is a specialized biotechnology firm founded in 2010 that develops, manufactures, and distributes high-quality immunodiagnostic assays, reagents, and ELISA kits for biomedical research and clinical diagnostics. The company leverages in-house antibody development and characterization capabilities to create immunoassays targeting clinically significant biomarkers. Ansh Labs offers validated ELISA immunoassays with rapid turnaround times, high specificity, and excellent sensitivity—supporting 24-month shelf lives and straightforward procedures. Core service offerings include contract development of custom immunoassays, immunoassay method development and validation, assay optimization, cross-reactivity testing, and preclinical biomarker testing. The company serves life science researchers, hospitals, commercial laboratories, and public health agencies, with particular expertise in areas such as cancer diagnostics, fertility biomarker testing, obesity research, and specialty assays for glucagon regulation and reproductive health. Following its acquisition by VION Biosciences in August 2024, Ansh Labs continues to maintain its team and product portfolio while expanding its service capabilities.

Phoenix Diagnostics is an in vitro diagnostics (IVD) manufacturer specializing in consumables for blood gas, electrolyte, and chemistry analyzers. The company manufactures quality controls, calibrators, reagents, and electrodes with over 50 years of industry experience. Product coverage encompasses more than 50 analyzer models from major manufacturers including Siemens (Bayer/Corning), Radiometer, Werfen (IL), Abbott Point of Care, Beckman Coulter, Roche Diagnostics, IDEXX Laboratories, Medica Corporation, Nova Biomedical, and Tokyo-Boeki. Phoenix manufactures over 90% of its product line in-house, enabling direct technical support and rapid custom solutions. The company serves clinical laboratories, hospitals, and international dealers and distributors. Product lines include blood gas and ISE controls, linearity controls, and electrodes compatible with major clinical laboratory platforms. The company offers private label contracting and custom manufacture capabilities, along with a Rapid-Stat QC program. No specific FDA, ISO, or other regulatory certifications are mentioned on the website.

BBI Solutions is a UK-based biotechnology company founded in 1986, specializing in high-quality reagents, antibodies, antigens, enzymes, and related services for the diagnostics and life sciences industries. Headquartered in Cardiff with seven facilities worldwide and ~400 employees, BBI offers native and recombinant reagents that power over 5 billion annual glucose strips and 400 million lateral flow tests globally. Core products include gold nanoparticles and conjugates, enzymes, antibodies, antigens, cell culture reagents, human serum controls, and stabilizers. The company provides comprehensive contract manufacturing and development services: antibody discovery and manufacturing (up to 5g scale), custom antigen development, gold conjugation (600+ conjugations annually), and lateral flow assay design through production in ISO 13485-certified cleanrooms. BBI's expert teams troubleshoot assay performance, tailor formulations, and provide regulatory support to accelerate IVD and life sciences partners' progress from concept to commercialization.

C.R. Bard (now part of BD) is a diversified global medical technology company operating through multiple business segments: BD Interventional, BD Life Sciences, and BD Medical. The company manufactures and distributes an extensive portfolio of medical devices, consumables, and diagnostic solutions across vascular access, medication delivery, infection prevention, laboratory diagnostics, surgical instruments, and specialty medical equipment. Through the Medivance acquisition (2011), Bard offers the Arctic Sun™ Targeted Temperature Management system for precise patient temperature control in critical care settings. The company serves hospitals, healthcare systems, clinical laboratories, and other healthcare facilities with products spanning syringes and needles, catheters (central and peripheral), infusion systems, surgical mesh and grafts, diagnostic culture media, molecular testing systems, blood collection products, stents, and specialty equipment for urology, cardiology, gynecology, and interventional medicine. With thousands of SKUs across therapeutic areas including vascular surgery, gastrointestinal care, wound management, and microbiology solutions, Bard functions as a comprehensive B2B medical device and consumables supplier.

Kedrion Biopharma is an international biopharmaceutical company headquartered in Barga, Tuscany, Italy, and a leading player in plasma-derived therapeutics. Founded in 2001, Kedrion collects, fractionates, produces, and distributes plasma-derived medicinal products treating coagulation disorders, neurological disorders, primary and secondary immunodeficiencies, and rare genetic disorders. The company operates 68 plasma collection centers in the US and seven production facilities across five countries, serving over 100 countries globally. With approximately 5,200 employees and a portfolio of 38 plasma-derived products, Kedrion is the fifth-largest plasma therapeutics manufacturer worldwide. The company emphasizes research and development of orphan drugs and novel therapeutic proteins, sustainability initiatives, and contract manufacturing services. Notable recent approvals include QIVIGY® and orphan drug designations for aceruloplasminemia treatments. Kedrion demonstrated 10% revenue growth in 2024.

LumiQuick Diagnostics Inc. is a minority-owned, privately-held manufacturer of high-quality point-of-care testing and immunoassay kits for the global in vitro diagnostics market. Founded in 2006 and based in Santa Clara, California, the company develops rapid diagnostic tests in multiple formats including test cups, cards, dip tests, and multi-panels. Product lines span infectious disease detection (Dengue, Zika, Chikungunya, COVID-19), drugs of abuse screening, disease markers for cardiac and cancer indicators, fertility hormones, vitamin D assessment, oxidative stress measurement, veterinary diagnostics, food safety testing, and biological threat agent identification. LumiQuick's QuickProfile™ branded assays leverage immunochromatographic technology for qualitative and quantitative detection. The company also manufactures ELISA-based platforms and offers the FDA EUA-cleared Boson Rapid SARS-CoV-2 Antigen Home Test. Products are sold in bulk through local and international distributors, targeting clinical laboratories, point-of-care settings, and compliance screening applications.

Dealmed Medical Supplies LLC is a B2B medical supply distributor serving physicians, healthcare facilities, surgical centers, urgent care, dialysis facilities, health systems, emergency medical services, and retail channels across the United States. The company operates as an authorized distributor for nearly 300 brands, offering a comprehensive product portfolio spanning medical and surgical consumables, medical and office equipment, physician laboratory supplies and diagnostics kits, office management supplies, and pharmaceuticals. Product lines include examination gloves (nitrile), surgical gauze sponges, adhesive bandages, surgical tape, suture and staple removal kits, examination tables, patient monitoring systems (Welch Allyn Connex Spot Monitor), spirometers (NDD EasyOne Air), clinical laboratory analyzers (Diatron Abacus, Quidel Sofia), rapid diagnostic tests (Strep A, COVID-19 antigen, influenza), steam sterilizers (Midmark M11), drape sheets, table paper, emesis basins, underpads, and injectable pharmaceuticals including naloxone, calcium chloride, diphenhydramine, aspirin, and cyanocobalamin. Dealmed operates multiple distribution centers leveraging proprietary logistics technology to enable fast fulfillment through its own fleet and major carriers. The company provides Dealmed Runtime™, a proprietary online ordering and management platform offering automatic reporting, inventory alerts, and supply chain visibility. Services include GPO contract integration, 3PL capabilities, custom shipping solutions, and consultative procurement support. Dealmed markets itself on operational agility, guaranteed product authenticity and warranty coverage, and omnichannel distribution reach. Founded in 2008, the company serves diverse care models from individual practices to large integrated delivery networks and government/public sector entities.

SiPhox Health is a Burlington, Massachusetts-based health diagnostics company specializing in silicon photonic biosensor technology for at-home blood testing and biomarker analysis. Founded in 2020 and backed by Y Combinator, Khosla Ventures, and Intel Capital, the company has delivered over 300,000 biomarker test results. SiPhox's proprietary EasyDraw kit enables painless upper-arm blood collection without needles or lab visits, with samples processed at CLIA-certified labs. The platform analyzes up to 60 biomarkers across cardiovascular, metabolic, hormonal, thyroid, liver, kidney, inflammation, and nutritional health. Beyond testing, SiPhox provides a centralized health dashboard with wearable integration (Apple Watch, Oura Ring, Fitbit), personalized supplement recommendations, lifestyle coaching, telehealth support, and an AI assistant (Sai) for result interpretation. The company targets chronic disease prevention and health optimization through evidence-based biomarker tracking and actionable insights.

CSL Behring LLC is a global biotechnology company specializing in plasma-derived and recombinant biotherapies for rare and serious diseases. The company manufactures and distributes immunoglobulins, clotting factor concentrates for hemophilia and bleeding disorders, therapies for immunodeficiencies, treatments for hereditary angioedema, and Alpha-1 antitrypsin deficiency products. As part of the larger CSL Limited group (founded 1916), CSL Behring operates manufacturing and distribution networks across over 100 countries, with significant recent investment ($1.5 billion) in U.S. plasma-based medicine manufacturing. The company emphasizes quality management, regulatory compliance, and innovation in cell culture reagents and plasma collection infrastructure. CSL's broader portfolio includes CSL Seqirus (vaccines, including influenza and pandemic preparedness), CSL Vifor (iron deficiency and nephrology/dialysis therapies), and CSL Plasma (plasma source plasma collection). With over 25,000 employees globally, the organization focuses on delivering life-saving therapies for bleeding disorders, immune system conditions, and chronic kidney disease.

Diamond Diagnostics Inc. is a specialized clinical laboratory instrumentation and consumables supplier based in Holliston, Massachusetts, founded in 1996. The company manufactures, remanufactures, and supplies new and refurbished chemistry analyzers, electrolyte analyzers, immunoassay systems, blood gas analyzers, coagulation analyzers, hematology analyzers, and molecular analyzers. With approximately 80 employees and ~$19M annual revenue, Diamond offers over 500 consumable products including reagents, quality controls, and electrodes. The company's proprietary Down-To-Frame® refurbishment process restores equipment to like-new condition. Most products hold FDA clearance and CE approval. Diamond provides comprehensive field service, depot service, preventive maintenance, remote support, control assay, and refurbishment services to clinical laboratories and hospitals globally. ISO 9001:2015 and ISO 13485:2016 certified, the company also offers OEM and contract manufacturing for third-party organizations.

Entegrion, Inc. is a life sciences company specializing in viscoelastic coagulation monitoring (VCM) systems for rapid hemostasis assessment. The company develops point-of-care diagnostic instruments designed to measure blood coagulation in real-time, enabling clinicians to manage hemostasis and coagulopathies across trauma, surgery, obstetrics, and emergency medicine settings. The VCM system uses fully automated testing with fresh whole blood—no chemical accelerants or sample manipulation required—making it suitable for bedside and pre-hospital applications. The device features a portable footprint optimized for multiple clinical environments. Entegrion's products address both civilian and military medicine needs; the U.S. Department of Defense has invested over $100 million in the company's product development since inception. The VCM has achieved CE Mark regulatory clearance in Europe and other regions accepting CE-marked devices; however, it has not yet received FDA 510(k) clearance for human clinical use in the United States. The company also offers VCMVet for veterinary coagulation monitoring and VCM Cascade for human applications. Leadership includes experienced healthcare executives and clinicians with backgrounds in emergency medicine, hematology, laboratory diagnostics, and transfusion medicine. The organization combines R&D, clinical validation, and regulatory expertise to bring complex laboratory tests to point-of-care settings.

Revvity, Inc. is a comprehensive life science solutions provider serving academia, pharmaceutical, biotech, clinical laboratories, contract research organizations, and healthcare professionals globally. The company operates across the drug discovery-to-diagnostics continuum, delivering integrated workflows in translational multi-omics, biomarker identification, imaging, screening, detection, diagnosis, and informatics. Product portfolio includes high-content screening instruments (Opera Phenix, EnVision plate readers), optical imaging systems (IVIS), cell analysis instruments (Cellometer), sample preparation equipment (Omni Bead Ruptor Elite homogenizers), and laboratory automation (Fontus workstations, LabChip systems). Reagent brands encompass BioLegend antibodies and flow cytometry reagents, AlphaLISA and SureFire immunoassays, HTRF TR-FRET assays, Dharmacon RNAi and CRISPR tools, and custom oligonucleotide synthesis. Representative diagnostic and clinical service offerings include newborn screening (33M+ annual screens), immunodiagnostics via EUROIMMUN solutions (85M+ blood samples analyzed), infectious disease serology, TB testing (T-SPOT.TB, 20M+ tested since 2002), reproductive health solutions (maternal/prenatal testing, cell-free DNA analysis, preeclampsia management), and clinical genomics services (300M+ tests performed). Licensing portfolio covers gene expression, editing, and viral vector technologies including LentiBOOST and Pin-point base editing platforms. Revvity serves 94% of top 50 global pharma companies, maintains ~11,000 employees worldwide, and operates on-site manufacturing, viral vector engineering, preclinical oncology services, and clinical testing. Regulatory presence includes FDA and CE approvals across diagnostics and instruments. The company integrates acquisition-driven growth with organic R&D, supporting discovery through clinical deployment across life science workflows.

Roche Diagnostics is a global leader in in vitro diagnostic (IVD) instruments, assays, and laboratory systems for clinical chemistry, molecular diagnostics, pathology, and specialty testing. The company manufactures high-volume automated analyzer platforms including the cobas® c 703 for clinical chemistry (2,000 tests/hour), cobas® 5800 system for consolidated automation and integration, and Digital LightCycler® System for digital PCR applications. Product offerings span core lab chemistry, hematology, immunochemistry, mass spectrometry solutions (including Ionify® steroid assays), tissue diagnostics with ready-to-use oncology assays, and blood-based biomarker testing (e.g., pTau181 for Alzheimer's-related amyloid pathology). The organization serves laboratory professionals, clinicians, researchers, and patients across multiple laboratory settings. Roche maintains FDA clearances and 510(k) approvals for its analytical systems and assays, with CLIA moderate-complexity categorization for specialized tests. The company provides comprehensive support including eLabDoc document library access (800,000+ documents), e-learning platforms, PACE/CEU accredited training, and clinical education resources. Manufacturing and regulatory operations are supported from US facilities including Indianapolis headquarters.

Renalytix is an AI-enabled in vitro diagnostics company specializing in chronic kidney disease (CKD) management, particularly diabetic kidney disease (DKD). The company's flagship product, KidneyIntelX.dkd, combines proprietary AI algorithms with blood-based biomarker analysis, genetic data, and electronic health record integration to generate patient risk stratification scores for progressive kidney function decline. The test received FDA marketing authorization in Q2 2023 and Medicare coverage determination in June 2024. KidneyIntelX enables early identification of high-risk patients with type 2 diabetes and CKD stages 1-3b, allowing clinicians to optimize treatment targeting and resource allocation to slow or prevent disease progression. Renalytix operates CLIA-certified clinical laboratories and partners with major healthcare systems including Mount Sinai Health System, University of Michigan, and Singing River Health System. The company also provides biomarker discovery and drug development support services to pharmaceutical partners. With a focus on shifting kidney disease management from reactive treatment to proactive health optimization, Renalytix addresses a significant public health need affecting over 850 million people globally.

Planet Innovation is a full-service healthtech innovation, commercialization, and manufacturing company based in Victoria, Australia, with additional facilities in Irvine, California. Founded in 2009, the company employs over 300 experts delivering end-to-end contract development and manufacturing (CDMO) services across the product lifecycle. Certified to ISO 13485, Planet Innovation specializes in diagnostics, medical devices, biotechnology, and connected health solutions. The company provides comprehensive services including product design and engineering, commercialization strategy, digital health solutions, and contract manufacturing. Its market-pull approach leverages deep market insights to ensure products meet customer needs and achieve commercial success. Planet Innovation collaborates with leading global healthtech companies including Abbott, Merck, Quidel, Bio-Rad, and IDEX. The company has expanded capabilities through strategic acquisitions and partnerships, enhancing manufacturing capacity and expertise in digital health, patient monitoring, and emerging medtech areas.

Q-linea AB is a Swedish infection diagnostics company founded in 2008, specializing in rapid antimicrobial susceptibility testing (AST) systems for sepsis and bloodstream infection management. The company's flagship product, ASTar, is a fully automated, CE-IVD marked system that delivers antibiotic susceptibility profiles directly from positive blood cultures in approximately six hours—significantly faster than traditional methods that require 48+ hours. ASTar operates with minimal hands-on time (less than two minutes) and provides accurate MIC (minimum inhibitory concentration) values through controlled inoculum protocols, integrating with electronic medical records for seamless laboratory workflows. Q-linea addresses a critical clinical need: sepsis affects approximately 50 million people globally each year with 11 million deaths, making rapid diagnosis and appropriate antibiotic selection essential for patient survival. The company holds CE-IVD approval in Europe and FDA 510(k) clearance in the US, and collaborates with partners like Thermo Fisher Scientific for product commercialization. Q-linea's mission focuses on improving sepsis treatment outcomes while reducing unnecessary antibiotic use and combating antimicrobial resistance.

BioMedica Diagnostics Inc. is a specialized B2B diagnostics manufacturer founded in 1999, headquartered in Windsor, Ontario, Canada. The company operates a 49,000 sq ft ISO 13485:2016 and MDSAP-certified facility focused on thrombosis and haemostasis diagnostics. BioMedica develops and manufactures customized reagents, coagulometers, prothrombin time tests, fibrinogen assays, D-dimer assays, and over 15 portable diagnostic systems for clinical laboratory use. The company provides contract manufacturing and OEM production services, supporting research institutions, clinical laboratories, and healthcare stakeholders across 70+ countries. BioMedica combines R&D expertise with fully automated manufacturing capabilities, offering scalable solutions from pilot lot development through commercial-scale production for in vitro diagnostics, veterinary applications, and thrombotic risk assessment.

Infitek is a professional manufacturer of laboratory and medical equipment based in Shanghai, China, established in 2010. The company specializes in scientific instruments and medical devices for pharmaceutical, biopharmaceutical, and clinical laboratory applications. With 18 manufacturing facilities and certifications including ISO 9001 and ISO 13485, Infitek serves over 176 countries globally. The company's product portfolio encompasses incubators, refrigeration equipment, centrifuges, spectrophotometers, autoclaves, gas chromatographs, real-time PCR systems, hematology analyzers, and comprehensive sample preparation and analysis equipment. Infitek provides integrated solutions for pharmaceutical workflows, clinical diagnostics, and laboratory automation, complemented by purchasing and inspection services in China and comprehensive after-sales support.

Kashi Clinical Laboratories is a fully accredited clinical laboratory founded in 2006 and based in Portland, Oregon, specializing in high-quality molecular diagnostic testing, consultative services, and customized assay development. The laboratory offers comprehensive testing services including molecular genetic tests, HLA and transplant services, genomic and oncology services, virology, toxicology, pharmacogenetics (drug metabolism), and clinical pathology. Kashi provides pre- and post-transplant testing, SNP testing, KIR typing, HLA antibody screening and identification, engraftment monitoring, and environmental testing. The lab operates the Molecular Microscope™ (MMDx™) diagnostic system and emphasizes rapid turnaround times, EHR integration, and consultative partnerships with healthcare providers. Services span chemistry, immunology, hematology, coagulation, microbiology, and urinalysis, with a commitment to rigorous standards and personalized customer service.

Grifols is a leading global biopharmaceutical and healthcare company founded in 1909, headquartered in Barcelona with significant US operations. The company operates across four primary business divisions: Biopharma (plasma-derived medicines and biopharmaceuticals for immunology, hepatology, intensive care, pulmonology, hematology, neurology, and infectious diseases), Diagnostic (blood screening and transfusion medicine diagnostics), Bio Supplies (plasma collection and processing supplies), and Healthcare Solutions for Hospitals (hospital equipment and consumables). Grifols manufactures and distributes innovative plasma-derived therapeutic products, clinical laboratory equipment and reagents, diagnostic assays, and healthcare infrastructure solutions for hospital and transfusion medicine settings. The company operates a global plasma donation center network and engages in research and development across multiple therapeutic areas, including immunological disorders, rare diseases, and infectious disease screening. Grifols maintains regulatory compliance with FDA approvals (evidenced by recent malaria blood screening assay approval), ISO standards, and international quality certifications. The company serves healthcare systems, blood banks, hospitals, clinical laboratories, and patients globally, with established operations and partnerships across the Americas, Europe, and Asia-Pacific regions.

TheraTest Labs delivers tailored in-practice diagnostic laboratory solutions focused on autoimmune disease testing and monitoring. The company provides a comprehensive platform combining specialist immunoassays, automated analyzers, and expert support services designed to help medical practices implement compliant in-house labs while maximizing revenue. With three decades of experience, TheraTest enables practices to offer timely diagnosis, prognosis, and therapeutic monitoring of autoimmune conditions through multiplex assays and cutting-edge diagnostic instrumentation. Their expert team ensures CLIA compliance and operational excellence, helping practices enhance net revenue by an average of $60k–$100k per provider annually.

Cliawaived, Inc. is a CLIA-waived medical testing and diagnostic supplies distributor serving clinical labs, physician offices, and home-use markets. The company supplies a broad range of point-of-care (POC) testing products including rapid drug screening tests (drug test cards and cups), infectious disease diagnostics (COVID-19, flu, RSV, mono, strep testing), STD/sexual health testing kits, urinalysis consumables, women's health tests, and general medical supplies. Product portfolio includes analyzers and meter devices (glucose monitors and similar POC analyzers), distributed under partnerships with established manufacturers such as Quidel. The company operates an e-commerce platform enabling B2B procurement of CLIA-waived test kits and supplies for clinical settings and direct-to-consumer home testing products. As a distributor of CLIA-waived diagnostics, Cliawaived serves urgent care centers, physician offices, occupational health programs (workplace drug screening), clinical laboratories, and patients seeking over-the-counter diagnostic testing. All products are CLIA-waived, meeting regulatory thresholds for simple test methodology and low clinical risk. The company maintains inventory of consumables and point-of-care instrumentation to support rapid deployment and same/next-day fulfillment for high-volume testing operations.

Tosoh Bioscience, a division of Tosoh Corporation (established 1935, Tokyo Stock Exchange listed), is a global provider of clinical diagnostic analyzers and separation & purification chromatography solutions. The Clinical Diagnostics division serves clinical laboratories, hospitals, and healthcare systems with immunoassay testing platforms and assays spanning oncology, diabetes, fertility, and endocrinology applications. The Separation & Purification division supplies liquid chromatography systems and consumables for biopharma, biotech, chemical, and research industries, with specializations in antibody analysis, biomolecule separation, oligonucleotide purification, and polymer characterization. Key product lines include the AIA-2000 high-throughput immunoassay analyzer, AIA-900 with automated sample handling, SkillPak pre-packed chromatography columns, and LenS3 MALS detector systems. The company operates manufacturing and service capabilities across multiple regions (US, Europe, Japan, China, India, Asia-Pacific) and supports bioprocess development, analytical testing, and research applications. Tosoh maintains a global workforce of over 14,000 across 100+ companies and serves principal markets in chemicals, bioscience, automotive, consumer electronics, and environmental sectors.

EUROIMMUN US Inc. is the North American subsidiary of Euroimmun, a leading German manufacturer of medical laboratory diagnostics founded in 1987. Operating in 18 countries with over 3,400 employees globally, the company specializes in innovative test systems, software, and automation solutions for diagnosing autoimmune diseases, infectious diseases, allergies, neurodegeneration, endocrinology, bone metabolism, and genetic analyses. Headquartered in Mountain Lakes, NJ, EUROIMMUN US supplies clinical laboratories with advanced immunodiagnostic reagents, microarray technologies, and chemiluminescence immunoassay (ChLIA) automation platforms. The company produces comprehensive antibody detection test systems and maintains ISO certifications, serving laboratory medicine professionals with high-quality, standardized diagnostic solutions for autoimmunity, infection control, and specialized clinical parameters.

OrSense is a medical device company specializing in non-invasive hemoglobin and blood analyte monitoring systems. The company develops and markets proprietary Occlusion Spectroscopy technology-based devices designed for rapid, painless screening of blood donors and patients. The NBM200 system, the flagship product, measures hemoglobin levels, oxygen saturation, and pulse rate using a reusable finger-ring sensor probe, eliminating the need for blood draws. With over 537,000 donors painlessly screened worldwide and installations in dozens of blood donation facilities, OrSense's technology reduces waste and improves operational efficiency. The company also offers SOLIS, a cloud-based inventory management and measurement delivery system for streamlined supply chain operations.

TECO Diagnostics is a US-based manufacturer of in vitro diagnostic (IVD) test kits and instrumentation headquartered in Anaheim, California, with 30+ years of experience serving over 100 countries. The company operates as an OEM and private-label partner, developing and manufacturing FDA-registered, CE-marked diagnostic products for global distribution. Product lines include urinalysis test strips, rapid diagnostic tests (including alcohol test strips), clinical chemistry reagents, women's health diagnostics, serology testing, animal health products, and laboratory instrumentation. The facility is cGMP-compliant, ISO 13485:2016 certified, and SA 8000 certified. TECO partners with major retailers including Walmart, Amazon, CVS, and Target. The company offers two business models: custom-branded OEM manufacturing for partners seeking private-label solutions, and direct distribution of established product lines. Their strategy team provides R&D support, product troubleshooting, and market-entry consultation. All products meet American manufacturing and quality standards with regulatory clearance for US and international markets.

bioMérieux is a global in vitro diagnostics leader headquartered in France, with significant US operations. The company manufactures and distributes comprehensive diagnostic solutions for clinical microbiology, molecular pathology, blood culture detection, immunoassays, and rapid point-of-care testing. Core competencies span microbial identification and antimicrobial susceptibility testing (ID/AST), sepsis diagnosis and management, infectious disease detection (respiratory pathogens, gastrointestinal pathogens), and blood culture systems. Key product platforms include BIOFIRE® FILMARRAY® multiplex PCR systems, VITEK® MS PRIME mass spectrometry, BACT/ALERT® VIRTUO® blood culture automation, and VIDAS® immunoassay analyzers. The company also serves pharmaceutical and food safety markets with quality control and environmental monitoring solutions. bioMérieux addresses critical clinical challenges including antimicrobial resistance (AMR) stewardship, rapid sepsis identification, and respiratory infection diagnostics. Offerings span hospital laboratories, point-of-care settings, and industrial applications. The company emphasizes diagnostic-driven clinical decision support, workflow automation, and integrated laboratory information management. Manufacturing includes automated detection systems, rapid molecular platforms, and MALDI-TOF mass spectrometry instruments. US operations distribute test kits, reagents, and instruments through multiple channels including direct sales and the bioMérieux eShop. The company holds multiple regulatory clearances including FDA 510(k) approvals and CE marking for diagnostic instruments and test kits.

Agilent Technologies is a global leader in laboratory instrumentation, software, supplies, and services serving over 285,000 laboratories across 110 countries. The company manufactures and distributes analytical instruments including liquid chromatography (LC/HPLC) systems, gas chromatography/mass spectrometry (GC/MS), atomic spectroscopy, and cell analysis platforms. Product lines include the 1290 Infinity III LC System with advanced detectors, BioTek Cytation 9 cell imaging multimode reader, and specialized HPLC columns for bio, small-molecule, and GPC/SEC applications. Agilent offers digital pathology solutions, PFAS testing kits, organic chemical standards, and CDMO (contract development and manufacturing organization) services. The company provides comprehensive CrossLab services including instrument maintenance, repair, digital connectivity solutions (CrossLab Connect), software upgrades, and technical training through webinars and educational programs. Agilent supplies consumables, columns, and standards for environmental and food testing, pharmaceutical analysis, and genomics applications. The company serves biopharma, pharmaceutical, environmental, energy, chemicals, semiconductor, and pathology sectors. Agilent emphasizes sustainability, circular economy principles, and supports STEM education globally through the Agilent Foundation.

Louisville APL Diagnostics manufactures in vitro diagnostic kits for the detection of antiphospholipid (aPL) antibodies, used in the diagnosis of Antiphospholipid Syndrome (APS). The company's FDA-cleared product portfolio includes the APhL ELISA Kit and APL ELISA Kit for detection of IgG, IgM, and IgA aPL antibodies; the LAPL aβ₂GPI HRP ELISA Kit for detection of IgG, IgM, and IgA anti-beta-2 Glycoprotein I antibodies; and calibrators and positive controls for anticardiolipin and β₂Glycoprotein 1 (for research use). Products are ELISA-based immunoassay reagents designed for clinical laboratory use in the diagnosis of APS, a thrombophilic disorder. The company maintains quality assurance protocols and regulatory compliance with FDA oversight. Louisville APL Diagnostics serves clinical laboratories, hematology and thrombosis centers, and research institutions requiring specialized diagnostic testing for antiphospholipid-related disorders.

Access Bio, Inc. is a global in vitro diagnostics (IVD) manufacturer headquartered in Monroe Township, New Jersey. The company specializes in rapid diagnostic tests and molecular diagnostics for infectious disease detection, with a primary focus on malaria, HIV, HPV, and COVID-19. Access Bio's product portfolio includes rapid point-of-care tests, COVID-19 antigen and molecular (PCR) assays, serology tests, and automated laboratory analyzers. The company has received multiple FDA Emergency Use Authorizations (EUA) for COVID-19 detection kits, including a 10-minute antigen test and molecular tests with results in 83 minutes or less. Access Bio serves international public health agencies, healthcare systems, and research organizations globally. The company holds FDA regulatory approvals and maintains manufacturing and distribution capabilities through established supply chain partnerships. Recent regulatory milestones include FDA-granted shelf-life extensions for the CareStart COVID-19 Antigen Home Test (extended to 21 months at 1–30°C storage). Access Bio is positioned as a leader in infectious disease diagnostics with operations across the US, South Korea, and other international markets. The company actively pursues partnerships with healthcare providers, educational institutions, and global health organizations to expand access to diagnostic solutions.

QuidelOrtho Corporation is a global in vitro diagnostics company providing diagnostic solutions across clinical laboratory, transfusion medicine, molecular testing, and point-of-care applications. The company offers over 550 assays across multiple testing modalities including real-time PCR, rapid lateral-flow immunoassays, automated immunohematology systems, and benchtop analyzers. Key product platforms include LYRA™ real-time PCR assays (open platform molecular testing), QUICKVUE™ rapid lateral-flow tests for infectious diseases and point-of-care diagnostics, TRIAGE™ System for point-of-care immunoassays, VITROS™ benchtop clinical chemistry systems, SOFIA™ 2 Analyzer for rapid diagnostics, ORTHO VISION™ Swift automated blood bank analyzers, ORTHO™ Workstation semi-automated immunohematology analyzer, and ORTHO OPTIX™ Reader for transfusion lab testing. The company serves clinical laboratories, hospitals, point-of-care settings, and home-testing markets in 140+ countries. QuidelOrtho recently completed acquisition of Lex Diagnostics, expanding its diagnostic portfolio. The company manufactures diagnostic instruments, reagents, and assays for infectious disease detection (virology, molecular, immunoassay), blood banking, clinical chemistry, and specialty testing. Products are regulated as in vitro diagnostic devices under FDA and international standards.

Babson Diagnostics operates BetterWay, a clinical laboratory and direct-to-consumer blood testing service offering fingerstick capillary blood collection at convenient locations. The company provides affordable, medically accurate blood tests with results delivered in 1–2 days. BetterWay's test menu includes comprehensive panels (Premium, Standard, Essential Checkup), specialty profiles (Heart Health, Fitness, Weight Loss, GLP-1, Thyroid), and routine chemistry and hematology panels (CMP, CBC, Lipid Panel, Iron Panel, Hepatic Function, Renal Function). Individual tests span cardiac markers (cholesterol, triglycerides, Lp(a), hsCRP), metabolic assessment (glucose, HbA1c), kidney function (creatinine, eGFR, BUN), liver enzymes (ALT, AST, ALP, bilirubin), electrolytes, proteins, hormones (TSH, Free T4, cortisol, vitamin D), CBC components (RBC, WBC differentials, platelets), and specialized markers (PSA, pregnancy hCG). Tests range from $15–$49. The company has published capillary equivalence studies in the Journal of Applied Laboratory Medicine (JALM) and serves consumers, clinicians, healthcare organizations, employers, payers, and retail pharmacy partners. BetterWay is available in Austin, Texas locations and expanding access through partner networks. The service emphasizes accessibility and affordability in blood testing.

Hemo bioscience is a North Carolina-based manufacturer of immunohematology reagents and blood banking diagnostics headquartered in Research Triangle Park. Founded over 20 years ago, the company specializes in transfusion diagnostics and serves blood banks, clinical laboratories, reference laboratories, buying groups, hospital blood banks, and donor centers. Their product portfolio includes blood typing reagents (including American Red Cross rare antisera), quality control materials for blood banking assays, red cell storage and treatment solutions (including DTT reagents), eluate kits for serological testing, validation and competency test kits, and proficiency testing materials. The ELU Clear Elution Kit (H360) is a flagship product available for direct purchase. The company manufactures high-quality reagents suitable for clinical laboratory and transfusion medicine applications. Their validation kits and educational materials support laboratory accreditation, competency assessment, and staff training. Products are distributed directly and through industry partners, with direct ordering available via phone and email.

Werfen is a global in vitro diagnostics company operating directly in over 30 countries and through distributors in more than 100 territories. The company develops, manufactures, and commercializes diagnostic systems, reagents, software, and services across hemostasis, acute care diagnostics, transfusion, autoimmunity, transplant, immunoassay, and clinical chemistry. Werfen's hemostasis portfolio includes in vitro diagnostic systems and reagents for diagnosing and guiding treatment of thrombotic and bleeding disorders. The acute care diagnostics line provides integrated whole-blood testing solutions for cardiovascular operating rooms, catheterization laboratories, intensive care units, and emergency departments. The transfusion division offers manual and automated solutions with serology reagents, fully automated instrumentation, data management software, and molecular products for donor-recipient compatibility. The autoimmunity segment delivers reagents and lab automation for diagnosing and monitoring autoimmune diseases. Transplant products feature molecular and antibody-based HLA assays and software for pretransplant compatibility determination and post-transplant monitoring. Clinical chemistry solutions serve chemistry and pharma-toxicology laboratories. Werfen also recently completed the acquisition of Omixon, a Budapest-based company specializing in next-generation sequencing technologies for transplant diagnostics. The company maintains a technology center in Bedford, Massachusetts, expanded in December 2024. Werfen's solutions are designed to improve patient care quality, reduce laboratory costs, ensure regulatory compliance, and enhance operational efficiency across clinical laboratory and acute care hospital settings.

Glycominds Diagnostics is a clinical laboratory diagnostics company specializing in non-invasive biomarker-based solutions for gastrointestinal diseases. The company develops and offers blood-based diagnostic tests for detection, prognosis, and monitoring of inflammatory bowel diseases (IBD), including Crohn's disease and Celiac disease. Product portfolio includes biomarkers for IBD diagnosis, Crohn's disease prognosis assessment, and monitoring of mucosal healing and anti-TNF therapy response. Glycominds positions its offerings as cost-effective alternatives to invasive diagnostic techniques such as endoscopy, providing gastroenterologists and primary care providers with accurate, non-invasive options for patient stratification and treatment monitoring. The company serves healthcare providers managing patients with gastrointestinal inflammatory conditions across multiple care settings.

Canon Medical Diagnostics USA is a global leader in multiplex allergy in vitro diagnostics. The company manufactures and distributes the OPTIGEN® Allergen-Specific IgE Assay, a comprehensive panel test designed for environmental and food allergen detection in clinical laboratory settings. The product line includes the AP3600™ Automated Instrument, a fully automated diagnostic platform for allergen-specific IgE testing, and the CLA-1™ Luminometer, a sensitive detection system for in vitro allergy diagnostics. These instruments and assays enable healthcare providers to deliver quality allergy care in a timely and cost-effective manner. The company serves clinical laboratories, allergology practices, and hospital laboratory systems. Products are designed for high-throughput multiplex testing of allergen-specific immunoglobulin E (IgE) antibodies, supporting diagnostic protocols in environmental and food allergy evaluation. Canon Medical Diagnostics USA operates from Mountain View, California, and maintains regulatory compliance with clinical laboratory diagnostic standards.

Trinity Biotech plc is a publicly listed clinical diagnostic products manufacturer specializing in blood analyzers, rapid immunoassays, and laboratory consumables. The company develops and markets diagnostic solutions across hematology, infectious disease, and metabolic screening. Key product lines include the Premier Resolution HPLC analyzer for hemoglobin variant and thalassemia detection; Uni-Gold HIV Complete rapid immunoassay for HIV-1/HIV-2 detection in serum, plasma, and whole blood; Bartels FlexTrans transport medium for specimen preservation; and Captia brand diagnostics. Trinity Biotech serves clinical laboratories, blood banks, and point-of-care settings globally. The company holds regulatory approvals including IFCC classification (Gold standard for HbA1c measurement on Premier Hb9210 system) and operates under offshored and outsourced manufacturing models to support supply chain efficiency. As a Nasdaq-listed entity, Trinity Biotech maintains compliance with regulatory and listing requirements, positioning itself as a supplier of high-quality, validated diagnostic instrumentation and consumables for clinical and research applications.